Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...

Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer. New Study Reveals How Bladder Cancer “Hijacks” the Immune System — Opening Door to ...

Novel intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer Phase 3 clinical trial met its primary endpoint ...

Researchers at EPFL, Heidelberg University and Roche have built a human mini-bladder to show how urine composition weakens bladder tissue, helping infections recur even after antibiotics. The work was ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor sasanlimab in patients with BCG-naïve, high-risk, non-muscle invasive bladder ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 - Effectiveness and Safety of a Flexible Dose Regimen for Patients ...